A Safety Net That May Not Be So Safe: Elan Sues Biogen Over J&J Deal
This article was originally published in The Pink Sheet Daily
Executive Summary
Elan's new deal with J&J over its key Alzheimer's assets runs into a brick wall: Biogen.
You may also be interested in...
Shareholder, Board Battles Heats Up at Elan
A proxy fight looms at Elan, which is beset by a new round of accusations over its corporate governance and conflicts of interest related to management.
Shareholder, Board Battles Heats Up at Elan
A proxy fight looms at Elan, which is beset by a new round of accusations over its corporate governance and conflicts of interest related to management.
Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q3 2009
Thanks to the return of the initial public offering and a strong market for follow-ons, money from public investors made a huge comeback during the third quarter of 2009. The merger and acquisition scorecard totaled $17.3 billion from 22 transactions--four of which topped the billion-dollar mark. And in alliances, most notable was Johnson & Johnson and Elan Corp. PLC's joint venture, which will acquire all of the assets and rights to Elan's Alzheimer's Immunotherapy Program.